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FMR1 mRnA from full mutation 
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Fragile X syndrome (FXS) is caused by a hypermethylated full mutation (FM) expansion with ≥ 200 
CGG repeats, and a decrease in FMR1 mRNA and its protein. However, incomplete silencing from 
FM alleles has been associated with more severe autism features in FXS males. This study compared 
scores on the Aberrant Behavior Checklist-Community-FXS version (ABC-CfX) in 62 males affected 
with FXS (3 to 32 years) stratified based on presence or absence of mosaicism and/or FMR1 mRnA 
silencing. Associations between ABC-CfX subscales and FMR1 mRNA levels, assessed using real-time 
PCR relative standard curve method, were also examined. The FXS group mosaic for premutation 
(PM: 55–199 CGGs) and FM alleles had lower irritability (p = 0.014) and inappropriate speech (p < 0.001) 
scores compared to males with only FM alleles and complete loss of FMR1 mRNA. The PM/FM mosaic 
group also showed lower inappropriate speech scores compared to the incomplete silencing (p = 0.002) 
group. Increased FMR1 mRNA levels were associated with greater irritability (p < 0.001), and lower 
health-related quality of life scores (p = 0.004), but only in the incomplete silencing FM-only group. The 
findings suggest that stratification based on CGG sizing and FMR1 mRNA levels may be warranted in 
future research and clinical trials utilising ABc‑cfX subscales as outcome measures.
Fragile X syndrome (FXS) is caused by a large trinucleotide CGG expansion (≥ 200 repeats), termed full muta-
tion (FM), in the promoter region of the Fragile X Mental Retardation 1 (FMR1)  gene1. FM alleles are associated 
with DNA methylation (DNAm) changes to the FMR1 promoter, resulting in decreased  transcription2 and little 
to no production of the Fragile X Mental Retardation Protein (FMRP). FXS is the leading single gene cause of 
intellectual disability (ID), with autism spectrum disorder (ASD) features also commonly occurring. Smaller 
premutation (PM) expansions (CGG: 55–199 repeats) typically have an unmethylated FMR1 promoter, but 
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elevated mRNA  levels3,4. This elevated FMR1 mRNA has been associated with “RNA gain of function” toxicity 
in some PM carriers and has been implicated in late onset disorders such as Fragile X-associated Tremor/Ataxia 
Syndrome (FXTAS)5. Rare unmethylated FM (UFM) alleles in adult individuals have been associated with neu-
rodegeneration observed as FXTAS, hypothesised to be related to “RNA gain of function” toxicity originating 
from UFM  alleles6–8.
There is now evidence from independent  studies9–11, demonstrating that in the majority of FM males, FMR1 
mRNA is not completely silenced (i.e., there is still residual transcription, even in the presence of FM alleles). 
These studies have reported that between 44 and 60% of FXS males express FMR1  mRNA4,10,11, with this incom-
plete silencing more recently associated with elevated ASD features in FM-only males, but not intellectual 
functioning  deficits11. This suggests that two reciprocal mechanisms, RNA toxicity and FMRP deficiency, may 
contribute to overlapping aspects of FXS, specifically ID and ASD features. This theory is supported by research 
demonstrating significant associations between FMR1 methylation and FMRP, and intellectual functioning 
 parameters12–14. However, relationships between FMR1 molecular variables and maladaptive behaviours assessed 
using the Aberrant Behavior Checklist-Community fragile X version (ABC-CFX)15—a tool often used as an 
outcome measure in clinical trials, have not been thoroughly investigated.
This study aimed to determine if maladaptive behaviours are increased, as measured by the ABC-CFX, in males 
affected with FXS with complete and incomplete silencing of FM alleles, as compared to males mosaic for PM and 
FM alleles. The study also explored relationships between the levels of FMR1 mRNA (if not completely silenced) 
in Peripheral Blood Mononuclear Cells (PBMCs) and each of the ABC-CFX subscale scores, total score, and the 
utility index. Based on our previous  study11, it was hypothesised that FM-only males with incomplete silencing of 
FM alleles would have elevated scores on the ABC-CFX compared to males with complete silencing of FM alleles.
Methods
Participants. Participants were Australian and Chilean males with FXS aged between 3 and 32 years old 
recruited into previous  studies11, 14. All participants had undergone fragile X genetic testing prior to recruitment 
using CGG PCR sizing and Southern blot analysis. Briefly, routine FXS testing involved first-line PCR-based 
assessment of CGG repeat size (± 1 CGG) with the upper limit of detection being 330 CGG and 170 CGG repeats 
for the  Chilean16 and  Australian17 samples, respectively. DNA samples from all males who showed a CGG size 
in the PM range or failed to show a PCR product, were reflexed for methylation sensitive Southern to confirm 
molecular diagnosis of  FXS18,19. Exclusionary criteria for the study included any other genetic conditions of 
known clinical significance, if they had any significant medical conditions (e.g., stroke, head trauma), and/or if 
they had inadequately controlled seizures.
Sample processing. PBMCs were isolated from 5 ml of blood collected in EDTA tubes, using Ficoll gra-
dient separation. RNA was then extracted from the isolated PBMCs using RNeasy kit as per manufacturer’s 
instructions (Qiagen, Global) for gene expression analyses.
FMR1 mRnA analysis. RNA (10 nanograms per sample) was reverse transcribed using the High Capac-
ity cDNA Reverse Transcription kit, as per manufacturer’s instructions (Thermo Fisher scientific, Global). The 
ViiaTM 7 system (Thermo Fisher Scientific, Global) was then used to analyse gene expression using the rela-
tive standard curve  method20. Specifically, a series of doubling dilutions of RNA (160–0.5 ng/µl) of a selected 
PBMC sample was performed for FMR1 5′ and 3′ mRNA assays and the two internal control genes (EIF4A2 
and SDHA), previously shown to be the optimal control gene combination of gene expression normalization in 
FMR1 related  disorders21. Previously published sequences were used for real-time PCR primers and probes for: 
FMR1 5′ assay targeting exon3/4  junction22; and FMR1 3′ assay targeting the exon13/exon14  junction23. FMR1 
primers and probes were used at 18 µM and 2 µM, respectively. EIF4A2 and SDHA primer/probe mixes were 
obtained from PrimerDesign (PerfectProbe gePP-12-hu kit) and used at concentration of 2 µM. Each sample was 
assayed in triplicate in a total volume of 10ul master-mix reaction. The FMR1 targeting reaction consisted of 5 µl 
of 2× SensiFAST Probe Low-rox Mix from SensiFAST™ Probe Low-ROX Kit (Bioline, Australia), 2.5 µl of RNase 
free water, 0.5 μl of TaqMan probe and 0.5 2 µM l forward and 0.5 2 µM l reverse primers, and 1 µl of the reverse 
transcription (cDNA) reaction. While EIF4A2 and SDHA qPCR reaction is made of 5 µl of 2× SensiFAST Probe 
Low-rox Mix from SensiFAST™ Probe Low-ROX Kit (Bioline, Australia), 3 µl of RNase free water, 1 μl Primer/
Probe mix, and 1 µl of cDNA reaction. The annealing temperature for thermal cycling protocol was 60 °C for 40 
cycles. Samples were quantified in arbitrary units (au) in relation to the standard curves performed on each plate 
with mean of three technical replicates being the representative value of relative FMR1 mRNA normalized by 
average internal control gene levels for each sample analysed.
intellectual functioning. Intellectual functioning was determined using an age- and language- (English 
or Spanish) appropriate Wechsler intelligence scale. Specifically, children aged 3  years to 6  years 11  months 
completed the Wechsler Preschool and Primary Scale of Intelligence-3rd Edition (WPPSI-III)  Australian24 and 
 Mexican25 Editions. Australian children aged 7 years to 16 years, 11 months completed the Wechsler Intelligence 
Scale for Children-4th edition (WISC-IV) Australian standardised  edition26 and Chilean children of the same 
age range completed the Wechsler Intelligence Scale for Children-3rd edition (WISC-III) Chilean  edition27. 
Participants aged 17+ years completed the Wechsler Adult Intelligence Scale-4th (WAIS-IV) Australian and New 
 Zealand28 and  Chilean29 editions.
Maladaptive behaviours. Maladaptive behaviours were assessed using the ABC-CFX15. The ABC-CFX has 
six subscales which measure irritability, lethargy, stereotypy, hyperactivity, inappropriate speech, social avoid-
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ance. An overall total score can also be calculated by summing up the scores obtained in each subscale. In the 
current sample these subscales demonstrated good internal consistency (Cronbach’s α = 0.82–0.94). The utility 
index (UI) to determine FXS health-related quality of life was also  used30. Higher scores on the subscales indicate 
greater impairment, while lower scores on the UI indicate poorer health-related quality of life.
procedure. Participants attended an appointment for assessment and venous blood collection. Parents/
caregivers completed the ABC-C at the time of assessment with the assistance of a research team member, if 
required. All procedures were approved by The Royal Children’s Hospital and INTA Human Research Ethics 
Committees (HREC #33066 and #15, respectively). All procedures were performed in accordance with these 
ethics approvals. All parents/caregivers provided written informed consent and those participants deemed cog-
nitively able also provided written informed consent.
Statistical analysis. Distribution for each demographic variable and maladaptive behaviours were nor-
mally distributed in each of three male groups, namely FM-only with complete silencing, FM-only with incom-
plete silencing and PM/FM mosaic, and therefore the mean and standard deviation were presented as summary 
statistics, and analysis of variance was used to compare the difference. Whereas for FMR1 mRNA, the distribu-
tion was not normally distributed in each group, the non-parametric Kruskal–Wallis test was used to compare 
the difference between the  three subgroups or Mann–Whitney U test for pairwise comparisons. For binary 
data (seizures, country and medication used) the percentage was given, and Fisher’s exact test was used for 
comparisons. While for maladaptive behaviours, analysis of covariance was used for comparisons, adjusting for 
age. Robust regression with robust standard error was used to assess the relationship between each maladaptive 
behaviour score (outcome) and FMR1 mRNA (predictor) for the combined data, adjusted for age and allelic 
class, and separately for FM-only with incomplete silencing and PM/FM mosaic, adjusted for age only. The dif-
ference in the relationship between these two groups was tested using an interaction term between subgroup 
(binary) and FMR1 mRNA levels. Significance of the interaction term indicated that the relationship was dif-
ferent between two subgroups. The Bonferroni correction method was used to correct for multiple testing. All 
analyses were conducted using Stata (https ://www.stata .com).
Results
The cohort of 62 males with FXS were split into three classifications: FM-only with complete FMR1 silencing, 
FM-only with incomplete FMR1 silencing, and PM/FM mosaics. These three groups did not significantly differ 
on age, intellectual functioning, and medication use (Table 1). One FM-only male displayed extremely elevated 
ABC-CFX scores that were atypical in comparison to the remainder of the group. This individual was excluded 
from the analyses so as not to affect the generalisability of the results. Key demographic and clinical information 
for those included in the analyses are in Table 1.
Table 1.  Demographic and clinical information. P-values highlighted in bold were significant prior to 
adjustment for multiple comparisons. FM full mutation, PM premutation, M mean, SD standard deviation, 
NA not applicable, FSIQ full scale IQ, ADOS CSS autism diagnostic observation schedule calibrated 
severity score, SSRI selective serotonin reuptake inhibitor, AAA alpha adrenergic agonist, SNRI selective 
norepinephrine reuptake inhibitor. p-value (p) for comparing the means between 1three groups; 2FM-only with 
complete silencing and FM-only with incomplete silencing; 3FM-only with compete silencing and PM/FM 
Mosaic; 4FM-only with incomplete silencing and PM/FM mosaic. *P-value remained < 0.05 after adjusting for 
multiple comparison using Bonferroni correction method.
FM-only with 
complete 
silencing
FM-only with 
incomplete 
silencing PM/FM mosaic
p1 p2 p3 p4n M ± SD n M ± SD n M ± SD
Age 19 14.6 ± 9.48 29 13.3 ± 7.29 14 16.8 ± 14.8 0.562 0.679 0.519 0.285
FSIQ 9 48.6 ± 13.4 18 43.9 ± 5.74 9 52.6 ± 9.06 0.067 0.211 0.351 0.024
ADOS CSS 17 6.06 ± 2.38 26 7.50 ± 1.45 12 6.67 ± 1.83 0.050 0.016* 0.390 0.205
Seizures (% lifetime presence) 19 10.5% 29 17.2% 12 0.0% 0.383 0.687 0.510 0.298
Country (% Australian) 19 15.8% 29 37.9% 14 42.9% 0.178 0.119 0.122 0.999
Medicated (% ≥ 1 medication) 19 52.6% 29 58.6% 14 28.6% 0.190 0.770 0.286 0.104
Stimulant 19 31.6% 29 27.6% 14 14.3% 0.566 0.999 0.416 0.456
SSRI 19 21.1% 29 27.6% 14 7.1% 0.318 0.739 0.366 0.231
Antipsychotic 19 5.3% 29 17.2% 14 7.1% 0.512 0.381 0.999 0.645
AAA 19 5.3% 29 0.0% 14 7.1% 0.279 0.396 0.999 0.326
SNRI 19 0.0% 29 0.0% 14 7.1% 0.226 NA 0.424 0.326
Benzodiazepine 19 0.0% 29 0.0% 14 7.1% 0.226 NA 0.424 0.326
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Comparison between the three FXS groups on FMR1 mRNA and ABC‑CFX scores. All three groups 
significantly differed from each other on FMR1 mRNA levels (Fig. 1A). The two FM-only groups did not signifi-
cantly differ on any of the ABC-CFX scores, though there was a trend towards more stereotyped behaviours in 
the complete silencing group (Table 2; Fig. 1B,C). The PM/FM mosaic group had significantly lower scores on 
the Irritability domain (Table 2; Fig. 1C) and ABC-CFX total score, as well as a significantly higher UI compared 
to the FM-only group with complete silencing (Table 2). Both FM-only groups had significantly elevated scores 
on the Inappropriate Speech domain compared to the PM/FM mosaic group (Table 2; Fig. 1B).
Relationships between FMR1 mRNA and ABC‑CFX scores. When the incomplete mRNA silencing and 
PM/FM mosaic groups were combined, no significant associations between FMR1 mRNA and ABC-CFX scores 
were observed (Table 3; Fig. 1D). When examining the specific allelic sub-groups, FMR1 mRNA was not signifi-
cantly associated with any of the ABC-CFX scores in the PM/FM mosaic male group (Table 3). In the incomplete 
silencing FM-only group, after Bonferroni correction, FMR1 mRNA was significantly associated with scores 
on the Irritability subscale, ABC-CFX Total and ABC-CFX UI (Table 3; Fig. 1D), and these relationships were all 
significantly different from that of the PM/FM mosaic group (p < 0.001, 0.005 and 0.001, respectively; Table 3).
Discussion
This study for the first time reports intergroup comparisons of the behavioural phenotype, as measured by 
the ABC-CFX, between FXS males stratified based on the presence or absence of FMR1 mRNA and CGG size 
mosaicism. It also reports novel associations between FMR1 mRNA and ABC-CFX scores in FXS. One of the 
key findings of this study is that stratification of the FM-only incomplete FMR1 silencing and PM/FM mosaic 
groups revealed significant associations between mRNA levels and Irritability scores, ABC-CFX total scores, and 
the UI, while no significant associations were observed when these two groups were combined. The study found 
elevated FMR1 mRNA levels were associated with more severe irritability symptoms and maladaptive behaviours 
Figure 1.  Intergroup comparisons and relationship between FMR1 mRNA levels in PBMCs and ABC-
CFX sub-scales in FM only and PM/FM mosaic males. Intergroup comparisons for (A) normalized FMR1 
mRNA levels; Note: Broken parallel lines represent minimum (MIN), maximum (MAX) and median (MED) 
mRNA values from TD controls (n = 14), from a previous  study11. Intergroup comparisons for (B) ABC-CFX 
Inappropriate speech scores; and (C) ABC-CFX Irritability scores between FM only and PM/FM mosaic males. 
(D) Relationship between normalized FMR1 mRNA levels and ABC-CFX Irritability score, with open and closed 
circles representing PM/FM mosaic and FM only incomplete silencing groups, respectively.
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generally (ABC-CFX total scores) and lower parent reported health-related quality of life (ABC-CFX UI) in males 
with incompletely silenced FM alleles more specifically.
The findings in the incomplete silencing group suggest reactivation of large expanded alleles may have a toxic 
gain of function, particularly in terms of irritability. Taken together with our previous  findings11, it is evident 
that residual mRNA from transcribed FM alleles has negative implications for behavioural outcomes in males 
with FM-only alleles. It is also possible that this may be explained by some of the individuals in the incomplete 
silencing group, harbouring a portion of PM or unmethylated FM alleles that are expressed and may be toxic in 
some cells. Further studies in larger, independent cohorts would assist in furthering our understanding of the 
impact of residual FMR1 mRNA on the FXS behavioural phenotype. The findings also highlight that combining 
PM/FM mosaic and FM-only males with incomplete silencing may ‘wash out’ any relationships observed between 
FMR1 mRNA levels and ABC-CFX-related clinical data, and also any effect of medications used in clinical trials.
This has been exemplified in the randomised placebo controlled trial of mavoglurant, an mGluR5 antagonist. 
Interestingly, this earlier study demonstrated no significant effects between mavoglurant and placebo from base-
line to follow up on ABC-CFX total scores in 30 males (18–36 years) with  FXS31. However, when those individuals 
with a fully methylated promoter and FMR1 mRNA silencing (n = 7) were analysed separately as a sub-group, 
significant improvements were seen from baseline to day 19 or 20 of treatment on ABC-CFX total scores, for all 
these patients. In examining those with partial methylation, some individuals showed improvement and others 
demonstrated a worsening of maladaptive behaviours. The authors theorised that the variation in treatment 
response among those with partial methylation may be explained by the variation in FMR1 mRNA and FMRP 
Table 2.  Comparison between complete and incomplete silencing FMR1 mRNA in FM-only males and PM/
FM mosaics on maladaptive behaviours. P-values highlighted in bold were significant prior to adjustment for 
multiple comparisons. Comparisons were conducted using analysis of covariance, adjusted for age; FM full 
mutation, PM premutation, M mean, SD standard deviation, ABC aberrant behavior checklist, UI utility index. 
p-value (p) for comparing the means between 1three groups; 2FM-only with complete silencing and FM-only 
with incomplete silencing; 3FM-only with compete silencing and PM/FM Mosaic; 4FM-only with incomplete 
silencing and PM/FM mosaic. *p-value remained < 0.05 after adjusting for multiple comparison of the three 
pairwise tests using Bonferroni correction method.
FM-only 
with 
complete 
silencing
(N = 19)
FM-only 
with 
incomplete 
silencing
(N = 29)
PM/FM 
mosaic
(N = 14)
p1 p2 p3 p4M SD M SD M SD
Irritability 16.9 11.8 14.7 9.36 8.07 5.36 0.045 0.350 0.014* 0.066
Lethargy 5.79 3.78 6.93 4.64 4.93 3.75 0.472 0.414 0.700 0.252
Stereotypy 6.37 5.14 4.28 3.45 3.93 4.20 0.132 0.055 0.139 0.884
Hyperactivity 13.0 8.37 10.2 7.04 7.29 5.90 0.082 0.094 0.034 0.424
Inappropriate speech 6.11 2.38 4.76 3.09 2.21 2.52  < 0.001* 0.119  < 0.001* 0.002*
Social avoidance 3.95 3.19 3.69 2.02 2.93 3.32 0.595 0.732 0.318 0.442
ABC total 52.1 27.4 44.5 18.6 29.4 19.8 0.020 0.158 0.005* 0.074
ABC UI 0.57 0.19 0.60 0.14 0.72 0.13 0.030 0.415 0.010* 0.037
Table 3.  Relationship between each maladaptive behaviours (outcome) and FMR1 mRNA (predictor) by 
allelic sub-group. P-values highlighted in bold were significant prior to adjustment for multiple comparisons. 
Analyses were conducted using robust regression, adjusted for age and allelic class for combined data 
(“All” = FM only with incomplete silencing + PM/FM mosaic), while adjusted for age only in each of allelic 
subgroup; FM full mutation, PM premutation, β estimated regression coefficient, se standard error, ABC 
aberrant behavior checklist, UI utility index. *p-value (p) remained < 0.05 after adjusting for multiple 
comparison using Bonferroni correction method.
All
(n = 43)
FM-only with incomplete 
silencing
(n = 29)
PM/FM mosaic
(n = 14)
β s.e p β s.e p Β s.e p
Irritability 3.78 2.95 0.199 22.7 3.17  < 0.001* − 1.38 1.69 0.415
Lethargy 0.28 0.80 0.723 1.44 2.08 0.489 − 0.03 0.86 0.969
Stereotypy − 1.17 1.80 0.517 − 4.27 1.66 0.010 0.01 3.97 0.997
Hyperactivity − 0.15 1.80 0.932 2.58 5.96 0.665 − 1.12 1.24 0.367
Inappropriate speech − 1.69 1.57 0.282 0.66 4.59 0.886 − 1.41 1.19 0.239
Social avoidance 0.09 1.15 0.935 1.52 1.61 0.343 − 0.45 1.39 0.744
ABC total 1.93 5.72 0.736 22.4 7.11 0.002* − 3.66 5.96 0.539
ABC UI − 0.03 0.05 0.560 − 0.22 0.08 0.004* 0.01 0.05 0.870
6Vol:.(1234567890)
Scientific RepoRtS |        (2020) 10:11701  | https://doi.org/10.1038/s41598-020-68465-6
www.nature.com/scientificreports/
expression and that dosage may need to be reduced in these cases. Nonetheless, Berry-Kravis et al.31, reported 
the results of two randomised, double-blind, placebo-controlled trials on over 300 FXS patients using the same 
stratification method, and found no improvements in either group.
Of note in all these clinical trials participant inclusion criteria was a diagnosis of FXS described as either 
“confirmed by genetic testing”31, without further specification of the assays used and the CGG allelic class results, 
or simply defined as the presence of > 200 CGG repeats or a positive cytogenetic test accompanied by family his-
tory of  FXS32. Therefore these trials may have included individuals with CGG size mosaicism. Jacquemont and 
 colleagues32 noted that two FM males who were found to have FMR1 mRNA levels within the control range may 
have in fact been PM/FM mosaic, but CGG sizing was not performed to confirm this. However, this assump-
tion may only be partially true. As shown in Fig. 1, the FMR1 mRNA levels in our cohort of males with PM/
FM mosaicism partially overlapped with both the control and incomplete silencing FM-only groups. Therefore, 
there may have been more than two males with undetected PM/FM mosaicism in the Jacquemont cohort. Thus, 
results in these clinical trials may have differed if participants were stratified based on FMR1 mRNA levels and 
presence or absence of PM/FM mosaicism.
Although it was expected that males with incomplete FMR1 mRNA silencing would have significantly elevated 
scores on the ABC-CFX compared to those males with complete FMR1 mRNA silencing, this was not confirmed. 
This hypothesis was based on our previous findings demonstrating elevated ASD features, specifically more 
social affect difficulties, based on the Autism Diagnostic Observation Schedule-2nd edition (ADOS-2) in the 
incomplete silencing  group11. However, no statistically significant differences were observed between the two 
FM-only groups. Instead the results demonstrated that the FM-only complete silencing group had significantly 
elevated scores on the Irritability and Inappropriate Speech subscales and ABC-CFX total score compared to 
the PM/FM mosaic group. Additionally, the complete silencing group had a significantly lower ABC-CFX UI, 
indicating poorer parent reported health-related quality of life. The incomplete FMR1 silencing group also had 
significantly higher scores on the Inappropriate Speech subscale compared to the PM/FM mosaic group. Several 
factors may have contributed to the differences observed between this study and our previous study.
While both assessments relate to behavioural features that are commonly attributed to FXS, the ADOS-2 is 
undertaken by a trained clinician while the ABC-C is completed by the parent/caregiver. ADOS-2 assessors are 
required to undertake specialist training to identify autistic behaviours, whereas the ABC-C is completed by 
a parent/caregiver who may be less cognisant of the types and severity of these behaviours. Moreover, parent-
report measures, such as the ABC-C, may be biased by the prognostic information that is given at the time of 
diagnosis. In a larger sample of FXS males from which this cohort was drawn, no significant differences were 
found on ADOS-2 scores between FM-only and PM/FM mosaic  males11 and with the current sample the PM/FM 
mosaic group did not significantly differ to the two FM-only groups on ADOS calibrated severity scores (CSS), 
where ADOS-2 assessors were blinded to the allelic classification of the person being assessed. Nevertheless, 
the discrepancies in group differences in behavioural findings could also be underpinned by weak associations 
between ABC-CFX scores and ADOS-2 CSS. Although both measures target overall similar behavioural problems, 
the ABC-CFX subscales encompass some maladaptive behaviours which are not fully captured by the ADOS-2 
CSS and vice versa.
The use of the ABC-CFX may also contribute towards a lack of demonstrable efficacy in clinical trials. There 
are likely issues with biases based on the prognostic information parents are given about their child. It is plau-
sible that the lower baseline scores on the ABC-CFX for PM/FM mosaic males, as seen in the current study, may 
reduce the ability to observe clinically significant changes post treatment and may reduce effect sizes when 
combined with FM-only males, particularly if differences in ABC-CFX scores at baseline are not accounted for 
in statistical analyses.
Another issue is the use of an ABC-C total score. The original developers of this measure highlight that a total 
score was never recommended, with explicit instructions in the manual stating “it is inappropriate to compute 
a total aberrant score based on summation of all 58 items, as the subscales are largely independent”33. Thus, 
compilation of a total score represents no specific  construct34. While in the current study a significant association 
was observed between FMR1 mRNA and the total score in the incomplete silencing group this is predominantly 
driven by the Irritability subscale. The Irritability subscale of the ABC-CFX has been classified in the moderate to 
strong category of outcome measures for FXS and is increasingly used in clinical  trials35. However, this subscale 
itself was shown to encompass four latent factors including tantrums, self-harm, verbal outbursts, and negative 
affect in a large sample of adolescents with idiopathic  ASD36.
While parent-reports have their utility, development of objective outcome measures that complement and 
extend on parent reports are required. Furthermore, rather than using adapted versions of measures that were 
generated for general ID or other neurodevelopmental disorders, establishing FXS specific parent and clinician-
report measures would be more appropriate. While such processes are time consuming, this may ultimately lead 
to more sensitive measures for FXS clinical trials. Moreover, development of objective assessments that can be 
administered repeatedly without ‘learned’ effects would be advantageous.
Limitations. One of the main limitations of the current study is the inclusion of participants who were tak-
ing a psychoactive medication which may have impacted parent reports of behaviour. Intended and side effects 
of specific medications may also impact the specific behaviours that are reported on in the ABC-C37. However, 
the proportion of participants taking a psychoactive medication did not significantly differ between the three 
groups, and this same limitation is also applicable to most previous FXS studies. Future studies will explore 
relationships of ABC-CFX with other molecular variables including FMRP, ASFMR1 and FMR1 promoter meth-
ylation, to further explain heterogeneity in the phenotypes and underlying biological mechanisms in different 
sub-groups of FXS.
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Another limitation in the current study is the use of peripheral blood to analyse FMR1 mRNA levels. While 
peripheral tissues, such as blood, are a relatively non-invasive way to examine gene expression, such tissues may 
not be entirely reflective of gene expression in the brain. Nonetheless, the findings reported here, as well as our 
previous findings demonstrating associations between FMR1 mRNA in PBMCs with autistic  features11 and FMR1 
methylation in buccal epithelial cells and intellectual functioning in males with  FXS14, highlight the utility of 
using peripheral tissues to examine genotype–phenotype relationships.
conclusions
Despite advances in the understanding of the molecular underpinnings of FXS, clinical trials are yet to dem-
onstrate efficacy in humans. As technological advances are being made, the understanding of the biology of 
FXS becomes more complex, with the likelihood that many sub-groups of FXS exist and will emerge. This 
study highlights how different sub-groups (FM-only with complete FMR1 silencing, FM-only with incomplete 
FMR1 silencing, and PM/FM mosaics) demonstrate different associations and intergroup differences between 
molecular and clinical outcomes. Although associations could not be undertaken for the complete silencing 
group (all FMR1 mRNA values = 0), a large degree of variability was still seen on ABC-CFX scores, suggesting that 
factors other than loss of FMR1 mRNA are contributing to the phenotype heterogeneity and/or that molecular 
analyses in blood do not always reflect molecular changes observed in the brain and other tissues. Differences 
observed between FM only and PM/FM mosaic males on the ABC-CFX, in addition to the lack of associations 
with FMR1 mRNA levels and ABC-CFX scores in the PM/FM mosaic group highlight that patient stratification by 
presence or absence of PM/FM size mosaicism and/or incomplete silencing of FM allele mRNA may be valuable 
for participant stratification in future research and clinical trials.
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